Immunotherapy duo shows promise against tough kidney cancer
NCT ID NCT03075423
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This study tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) against standard treatments for people with a rare and advanced form of kidney cancer called non-clear cell renal cell carcinoma. The goal was to see if the combination could help patients live longer. About 316 participants who had not yet been treated for their advanced cancer took part in this phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre François Baclesse
Caen, France
-
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, France
-
Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
-
Centre Leon Berard
Lyon, France
-
Charite Berlin (Campus Virchow-Klinikum)
Berlin, Germany
-
Gent University Hospital (Universitair Ziekenhuis Gent)
Ghent, Belgium
-
Goethe University Frankfurt
Frankfurt am Main, D-60590, Germany
-
Heine University
Düsseldorf, Germany
-
Hospita de la Santa Creu i Sant Pau
Barcelona, Spain
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Univeritario 12 de Octubre
Madrid, Spain
-
Hospital Vall d'Hebron
Barcelona, Spain
-
Institut Gustave Roussy
Paris, France
-
Klinik für Urologie, Universitätsklinik
Jena, Germany
-
Klinikum Rechts der Isar der TU München
München, Germany
-
Les Hoptaux Universitaires de Strasbourg
Strasbourg, France
-
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
-
Nationales Zentrum für Tumorerkrankungen (NCT)
Heidelberg, 69120, Germany
-
Netherlands Cancer Institute
Amsterdam, Netherlands
-
Royal Free London NHS Foundation Trust
London, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
Thomayer Hospital
Prague, Czechia
-
University Hospital
Homburg/Saar, Germany
-
University Hospital Erlangen
Erlangen, 91054, Germany
-
University Hospital Greifswald
Greifswald, Germany
-
University Hospital Hradec Králové
Hradec Králové, Czechia
-
University Medical Center Groningen
Groningen, Netherlands
-
University of Muenster
Münster, 48149, Germany
-
Universitätsklinik Tübingen
Tübingen, Germany
-
Universitätsklinikum Essen
Essen, Germany
Conditions
Explore the condition pages connected to this study.